8月14日 - ** 药物开发商Schrodinger SDGR.O股价盘前大跌19.1%至16.05美元
** 该公司表示， (link)，它将停止开发治疗两种血癌的试验性疗法SGR-2921，因为在一项早期研究中，该疗法被认为导致了两名患者死亡。
** 患者安全是我们的第一要务，"SDGR 的医学负责人说。"虽然早期临床活动令人失望，但我们相信这对患者来说是正确的决定。
** 截至收盘，股价累计上涨 2.9
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.